Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Andrew Robbins is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention JAK2 V617F, all published on July 12, 2026.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Andrew Robbins is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention JAK2 V617F, all published on July 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering JAK2 V617F. Shared-story counts are live from our verified record — not editorial picks.
The biotech’s novel inhibitor could redefine the JAK2-targeted therapy landscape, with preclinical data supporting disease-modifying potential ahead of a planned IND submission this year. Investors watch for Phase 1 timing.
Source: insidermonkey.com · finance.yahoo.com
JAK2 V617F is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
